Conecte-se

Bibliografias temáticas / Post-Cancer / Artigos de revistas

Artigos de revistas sobre o tema "Post-Cancer"

Siga este link para ver outros tipos de publicações sobre o tema: Post-Cancer.

Autor: Grafiati

Publicado: 22 de junho de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Post-Cancer".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Mohamed Traore, Wend-Yam, Behyamet Onka, Ibrahima Dokal Diallo, Rachida Latib e Youssef Omor. "Post-radiotherapy recto-vaginal fistula in cervical cancer". International Journal of Case Reports and Images 13, n.º 2 (3 de outubro de 2022): 153–55. http://dx.doi.org/10.5348/101349z01wt2022ci.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Belyea, James, Robert Hart, Jonathan Trites e Mark Taylor. "Post Cancer Treatment". Otolaryngology–Head and Neck Surgery 143, n.º 2_suppl (agosto de 2010): P152. http://dx.doi.org/10.1016/j.otohns.2010.06.246.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Madhu, Deepak, Syed Anjum Gardezi e Nadeem Tehami. "Is post-endoscopic ultrasound pancreatic cancer analogous to post-colonoscopy colorectal cancer?" Endoscopy 55, n.º 01 (20 de dezembro de 2022): 102. http://dx.doi.org/10.1055/a-1881-4533.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Sharma, Abha. "Predictors of Post traumatic growth among breast cancer patients in Nepal". Asian Pacific Journal of Health Sciences 4, n.º 2 (30 de junho de 2017): 9–17. http://dx.doi.org/10.21276/apjhs.2017.4.2.3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Green, Nathan, Dale Treible e Harvey Wallace. "Prostate Cancer: Post-Irradiation Incontinence". Journal of Urology 144, n.º 2 Part 1 (agosto de 1990): 307–9. http://dx.doi.org/10.1016/s0022-5347(17)39438-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Huang, Andy, George Tsavellas e Kirsten S. Hindle. "Colorectal cancer surveillance post-surgery". Hospital Medicine 62, n.º 8 (agosto de 2001): 490–91. http://dx.doi.org/10.12968/hosp.2001.62.8.1626.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Maher, Ian, e Jeremy Bordeaux. "Post-Skin Cancer Alar Reconstruction". Facial Plastic Surgery 29, n.º 05 (13 de setembro de 2013): 351–64. http://dx.doi.org/10.1055/s-0033-1353375.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Audic, Yann, e Rebecca S. Hartley. "Post-transcriptional regulation in cancer". Biology of the Cell 96, n.º 7 (setembro de 2004): 479–98. http://dx.doi.org/10.1016/j.biolcel.2004.05.002.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Pradhan, S. A. "Post-cricoid cancer: An overview". Seminars in Surgical Oncology 5, n.º 5 (1989): 331–36. http://dx.doi.org/10.1002/ssu.2980050508.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Elshagie Habib Abdelmalak, E. "Prostate cancer surgery post infection". European Urology Open Science 59 (janeiro de 2024): S136. http://dx.doi.org/10.1016/s2666-1683(24)00123-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Meunier, M., M. Gaudé, A. Foncelle, L. Christophe, J. Berardet, S. Jacquin-Courtois e C. Confavreux. "Évaluation de la sarcopénie chez les patients en post-cancer : cohorte JUMP post-cancer". Revue du Rhumatisme 90 (dezembro de 2023): A285—A286. http://dx.doi.org/10.1016/j.rhum.2023.10.443.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Sriwong, Kittipat, Kittisak Kerdprasop e Nittaya Kerdprasop. "Post-Operative Life Expectancy of Lung Cancer Patients Predicted by Bayesian Network Model". International Journal of Machine Learning and Computing 8, n.º 3 (junho de 2018): 280–85. http://dx.doi.org/10.18178/ijmlc.2018.8.3.700.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Hope, Christopher Martin. "Immune profiling and cancer post transplantation". World Journal of Nephrology 4, n.º 1 (2015): 41. http://dx.doi.org/10.5527/wjn.v4.i1.41.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Smith, James. "AB008. Management of fertility post cancer". Translational Andrology and Urology 5, S1 (abril de 2016): AB008. http://dx.doi.org/10.21037/tau.2016.s008.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Devi, Mutum Sangeeta, e Asif Ahmed. "Oral manifestation of post cancer therapy". Journal of Dental Specialities 9, n.º 2 (15 de dezembro de 2021): 53–56. http://dx.doi.org/10.18231/j.jds.2021.014.

Texto completo da fonte

Resumo:

Oral cancer has become serious health issues. It is owing to a variety of factors including poor hygiene, tobacco usage, chewing tobacco, smoking, and others. Along with surgery and chemotherapy, the most common treatments include radiation therapy and chemotherapy. Patients with cancer may experience oral toxic effects as a result of antineoplastic therapy such as radiotherapy and chemotherapy. A variety of factors influence radiation, including the oral mucosa's fast cell turnover rate, the richness and complexity of the oral microbiota, and soft tissue stress during normal mouth function. The present literature review is for awareness regarding the main oral manifestation secondary to post cancer therapy.

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Semiglazov, V. F., M. A. Dzhelialova, S. S. Yerechshenko, E. T. Munaeva, R. S. Pesotsky, A. I. Tseluyko, A. S. Emelyanov, R. V. Donskikh e P. V. Krivorotko. "Post-neoadjuvant treatment of breast cancer". Meditsinskiy sovet = Medical Council, n.º 9 (30 de julho de 2020): 232–41. http://dx.doi.org/10.21518/2079-701x-2020-9-232-241.

Texto completo da fonte

Resumo:

Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual invasive disease following neoadjuvant chemotherapy, and the KATHERINE trial demonstrated a significant benefit of trastuzumabemtansine (TDM1) in patients with HER2-positive breast cancer who did not achieve a pathologic complete response, so we have a lot of interesting alternatives of post-neoadjuvant treatments for high-risk patients. The discovery of molecular markers of resistance to endocrinotherapy (cyclin-dependent kinases (CDK 4/6), ER mutation (ESR1), mTOR signaling pathway, co-expression of ER+/HER2+) and inhibitors to them expanded the possibilities of endocrinotherapy not only in advanced and metastatic breast cancer, but also in residual ER+ tumors. The pCR rates in hormone receptor-positive breast cancer after neoadjuvant chemotherapy are around 10%, which is much lower than the values observed in HER2-positive and triple negative subtypes, so new strategies are needed to improve pCR rates in this subgroup, even though the adjuvant endocrine therapy impacts significantly the outcomes of this patients. The cyclin-dependent kinases (CDKs) are serine–threonine kinases that regulate cell cycle progression from the G1 to the S-phase during mitosis. CDKs activity can be abnormally increased or dysregulated in breast cancer, leading to a constant stimulus for cell proliferation and survival, which is a known mechanism of resistance to endocrine treatment. The CDK inhibitors act on CDKs and block their activity, thereby restoring the cell cycle regulation. In studies with metastatic hormone receptor-positive breast cancer patients, the combination of a CDKis with first or second-line endocrine therapy showed significant improvements in progression-free survival and response rates. Evolving techniques such as next-generation sequencing and gene expression profiles have improved our understanding of the biology of residual disease and also the mechanisms involved in treatment resistance.

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

RACHERIU, Mihaela, Sînziana Călina SILIȘTEANU e Maria Ramona COCA. "Post-therapeutic lymphedema in breast cancer". Balneo Research Journal 10, Vol 10 No. 4 (10 de dezembro de 2019): 509–13. http://dx.doi.org/10.12680/balneo.2019.289.

Texto completo da fonte

Resumo:

Introductions. Lymphedema is an interstitial accumulation of protein-rich lymph fluid, due to the post-therapeutic alteration of lymphatic circulation in the upper limb. The appearance of lymphedema is favoured by a number of risk factors. All of these factors ultimately lead to a process of tissue fibrosis. Materials and methods. This study was carried out in an outpatient regimen, for a period of 12 months, in the kinetotherapy room, using massage elements for lymphatic drainage and kinetotherapy technique. The study group included 15 patients aged 27-65 years.Results and discutions. Patients evaluated the quality of life after surgery based on the physical and mental symptoms, which is why anxiety, pain reduction through massage and kinetotherapy give patients self-confidence as well as confidence in the recovery process. Conclusions. This complex programme that includes lymphatic drainage massage methods and kinetotherapy techniques should be applied individually, progressively, under the control of the kinetotherapist. Key words: lymphedema, kinetotherapy technique, lymphatic drainage massage,

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Fu, Mei R., Sheila H. Ridner e Jane Armer. "Post-Breast Cancer Lymphedema: Part 1". AJN, American Journal of Nursing 109, n.º 7 (julho de 2009): 48–54. http://dx.doi.org/10.1097/01.naj.0000357172.94131.58.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Fu, Mei R., Sheila H. Ridner e Jane Armer. "Post–Breast Cancer Lymphedema: Part 2". AJN, American Journal of Nursing 109, n.º 8 (agosto de 2009): 34–41. http://dx.doi.org/10.1097/01.naj.0000358492.91678.78.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Cordova, Matthew J., Michelle B. Riba e David Spiegel. "Post-traumatic stress disorder and cancer". Lancet Psychiatry 4, n.º 4 (abril de 2017): 330–38. http://dx.doi.org/10.1016/s2215-0366(17)30014-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Wöll, Ewald. "Upper gastrointestinal cancer: POST ASCO 2013". memo - Magazine of European Medical Oncology 6, n.º 3 (setembro de 2013): 220–21. http://dx.doi.org/10.1007/s12254-013-0105-9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Pall, Georg. "Post ASCO update 2016—lung cancer". memo - Magazine of European Medical Oncology 9, n.º 4 (dezembro de 2016): 215–18. http://dx.doi.org/10.1007/s12254-016-0302-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Fitzal, Florian. "Post San Antonio Breast Cancer Symposium". memo - Magazine of European Medical Oncology 10, n.º 2 (30 de maio de 2017): 50–51. http://dx.doi.org/10.1007/s12254-017-0334-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Wang, L. Y., e I. Ganly. "Post-treatment surveillance of thyroid cancer". European Journal of Surgical Oncology 44, n.º 3 (março de 2018): 357–66. http://dx.doi.org/10.1016/j.ejso.2017.07.004.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Jewer, Michael, Scott D. Findlay e Lynne-Marie Postovit. "Post-transcriptional regulation in cancer progression". Journal of Cell Communication and Signaling 6, n.º 4 (9 de outubro de 2012): 233–48. http://dx.doi.org/10.1007/s12079-012-0179-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Francis, Anna, Eric Au, Wai H. Lim e Germaine Wong. "Post-transplant cancer: An epidemiological evaluation". Journal of Onco-Nephrology 4, n.º 3 (14 de setembro de 2020): 145–52. http://dx.doi.org/10.1177/2399369320953869.

Texto completo da fonte

Resumo:

Kidney transplantation is a lifechanging event for patients with end-stage kidney disease (ESKD) because it improves the quality of life and survival of these patients. However, it is not a cure and is not without complications. Transplant recipients have an excess risk of premature death (largely from cancer and cardiovascular disease (CVD)) by at least 10-times compared to the general population. Published work has identified cancer as one of the most important and feared outcomes in transplant recipients and is a key research priority recognised by both patients and health professionals. There is also convincing epidemiological evidence, suggesting the overall risk of developing cancer in the transplant population is approximately 2 to 3-fold higher compared to the age-matched general population. Unlike CVD, where the death rates have fallen considerably over the past decade in this population in response to better screening, preventative and intervention approaches, the excess risk of cancer-related deaths in transplant recipients remains at least 10-fold higher compared to cancer patients in the general population. The causes of the increased risk of death are unknown but may be a consequence of possible differences in tumour biology under the influence of immunosuppression. In this review, we will discuss the epidemiology of overall and site-specific cancer risk and death across different countries. We will also focus on the current evidence on the prevention and screening in our at-risk transplant candidates. Finally, management strategies of common cancers such as skin, post-transplant lymphoproliferative disease and solid organ cancers such as colorectal, breast and lung cancer will be evaluated.

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Peters, M. "A26 Management of post-cancer fatigue". European Journal of Oncology Nursing 14 (abril de 2010): S10—S11. http://dx.doi.org/10.1016/s1462-3889(10)70037-5.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Boonsiriphant, Piriya, Joel A. Hirsch, Alex M. Greenberg e Eric M. Genden. "Prosthodontic Considerations in Post-cancer Reconstructions". Oral and Maxillofacial Surgery Clinics of North America 27, n.º 2 (maio de 2015): 255–63. http://dx.doi.org/10.1016/j.coms.2015.01.007.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Prisyazhiuk, Anatoly, O. A. Pjatak, V. A. Buzanov, GillianK Reeves e Valerie Beral. "Cancer in the Ukraine, post-Chernobyl". Lancet 338, n.º 8778 (novembro de 1991): 1334–35. http://dx.doi.org/10.1016/0140-6736(91)92632-c.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

&NA;. "Immunosuppressants increase post-transplant cancer risk?" Inpharma Weekly &NA;, n.º 1570 (janeiro de 2007): 19. http://dx.doi.org/10.2165/00128413-200715700-00047.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Gofrit, Ofer, e Marina Orevi. "Post-operative surveillance in kidney cancer". Annals of Translational Medicine 7, S3 (julho de 2019): S136. http://dx.doi.org/10.21037/atm.2019.06.11.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Srivastava, Pranay, Bobby Jacob, Miral Subhani, Qi Tao e Kaleem Rizvon. "Post-Colonoscopy Rapidly Progressive Colorectal Cancer". American Journal of Gastroenterology 113, Supplement (outubro de 2018): S907—S908. http://dx.doi.org/10.14309/00000434-201810001-01577.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Sonenberg, Nahum, e Nissim Hay. "Cancer Genomics: the post-transcriptional era". Current Opinion in Genetics & Development 23, n.º 1 (fevereiro de 2013): 1–2. http://dx.doi.org/10.1016/j.gde.2013.02.016.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Kayukova, E. V., e E. S. Bolotov. "POST-COVID SYNDROME IN CANCER PATIENTS". Transbaikalian Medical Bulletin, n.º 1 (2023): 149–55. http://dx.doi.org/10.52485/19986173_2023_1_149.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

d’Estaing, Sandrine Giscard, e Céline Chalas. "Gamete quality for post-cancer use". Médecine de la Reproduction 26, n.º 1 (março de 2024): 49–54. http://dx.doi.org/10.1684/mte.2024.0993.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Horst, H. A., K. Bäuning, A. Friedl, A. Müller, R. D. Kanitz e D. Weisner. "Improvement of cancer patients post-clinical care by cancer registries". Journal of Cancer Research and Clinical Oncology 111, S1 (fevereiro de 1986): S62. http://dx.doi.org/10.1007/bf02580019.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Endo, Motoki, Go Muto, Yuya Imai, Kiyomi Mitsui, Katsuji Nishimura e Kazuhiko Hayashi. "Predictors of post-cancer diagnosis resignation among Japanese cancer survivors". Journal of Cancer Survivorship 14, n.º 2 (13 de novembro de 2019): 106–13. http://dx.doi.org/10.1007/s11764-019-00827-0.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Ross, Allyson, e Alison Mitchell. "Recovery in breast cancer - Areola micropigmentation post breast cancer surgery". European Journal of Surgical Oncology 50 (maio de 2024): 108177. http://dx.doi.org/10.1016/j.ejso.2024.108177.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Lee, Jeeyeon, Jisang Yu, Samuel Schellenberg, Il-Young Chung, Ankit Bharat e Young Kwang Chae. "Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junho de 2023): e21061-e21061. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21061.

Texto completo da fonte

Resumo:

e21061 Background: To evaluate the role of double lung transplantation (DLT) for lung cancer, the survival outcomes of patients who underwent DLT for lung cancer and the incidence of lung cancer after DLT were assessed. Methods: Data from case series reported in the literature were pooled and collected from the Organ Procurement Transplantation Network (OPTN) and the International Society of Heart and Lung Transplantation (ISHLT) registries. We evaluated the recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS) of patients who underwent DLT for lung cancer. Moreover, the incidence and OS of post-transplant lung cancer in patients who received transplants for the non-cancerous disease were examined. Results: Regarding patients who underwent DLT for lung cancer, in the pooled (n = 19), OPTN (n = 15), and ISHLT (n = 25) data, 5-year RFS was 52.6%, 66.7%, and 80.0%, and 5-year OS was 57.9%, 26.7%, and 36.0%, respectively. The median CSS was 48.0 (range, 6.0–144.0), 27.7 (range, 0.2–66.6), and 24.0 (range, 0.1–145.1) months. Additionally, the application of cardiopulmonary bypass was associated with lower tumor recurrence in the pooled data (p = 0.004). The incidence and 5-year OS post-transplant lung cancer in patients who underwent DLT for the non-cancerous disease were 0.8% and 47.3% in the OPTN data and 0.6% and 50.7% in the ISHLT data, respectively. Conclusions: We demonstrated that reasonable survival outcomes can be achieved with DLT in patients with bilateral lung cancer. Further studies are required to evaluate the risk of post-transplant lung cancer in patients undergoing DLT for bilateral lung cancer.

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

&NA;. "Immunosuppressants may increase cancer risk post-transplant". Reactions Weekly &NA;, n.º 1134 (janeiro de 2007): 1. http://dx.doi.org/10.2165/00128415-200711340-00001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Corrado, Ann Marie, e Monica L. Molinaro. "Post-traumatic growth following breast cancer treatment". University of Western Ontario Medical Journal 86, n.º 1 (29 de agosto de 2017): 14–15. http://dx.doi.org/10.5206/uwomj.v86i1.2138.

Texto completo da fonte

Resumo:

Worldwide, breast cancer is the most commonly diagnosed cancer amongst women. Currently, in Canada, it is estimated that approximately 1 in 9 women will develop breast cancer at some point in their life, and 1 in 30 will die from it. With the growing proportion of women diagnosed with breast cancer each year, there is an expanding body of literature addressing the effect of undergoing breast cancer treatment. The survival rate has increased since the mid-1980s, and as such, more women are in remission from their treatment. To coincide with this, breast cancer literature has begun addressing the effects experienced by women after their treatment. The purpose of this article is to briefly review literature that suggests that women may experience post-traumatic growth after completing breast cancer treatment. Post-traumatic growth, or experiencing positive outcomes as a result of undergoing an extremely negative or traumatic experience, can include developing a new perspective on life, adopting routines to enhance one’s quality of life (such as diet and exercise habits), as well as increasing spirituality. This article will outline some potential outcomes of post-traumatic growth, as well as provide insight to health care providers on how to aid in transitioning women with breast cancer from treatment to life in remission.

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

ALOUL, Adnan Al, Dan Florin UNGUREANU e Nicolae BACALBASA. "Post-resectional pelvic recurrences of rectal cancer". Romanian Journal of Medical Practice 16, n.º 2 (30 de junho de 2021): 202–6. http://dx.doi.org/10.37897/rjmp.2021.2.17.

Texto completo da fonte

Resumo:

Introduction. Pelvic recurrence is not a rare event after resection with curative intent for rectal cancer originating from different segments of the rectum (lower, intermediary and superior part). Material and methods. This retrospective observational study included 106 patients; among these cases there were 79 patients who accepted surgical treatment of rectal cancer (treated in a governmental hospital between 2014 and 2017) and who were submitted to anterior resection with Hartmann’s procedure (6.5% of patients), anterior resection of rectosigmoid with colorectal anastomosis (78% of cases) and abdominoperineal resection (15% of cases). Results. After a 2 year follow-up, pelvic recurrence was reported in 11patients ~ 14% of cases: 33% rate of recurrence after Hartmann procedure, 9% rate of recurrence after abdominoperineal resection, and 10% rate of recurrence after anterior resection of rectosigmoid with colorectal anastomosis. 39 patients (49% of cases) had been submitted to preoperative radiotherapy: the pelvic recurrence rate among these cases was of 11% (9 patients). The rate of recurrence (RR) was also significantly influenced by the stage at diagnostic: stage III had RR = 52% of cases, stage II had RR = 41% of cases and stage I had RR = 0% of cases). The survival rate among surgically treated patients after 1 one year was 86%, and 80% in the first 2 years after treatment. Conclusions. Rectal cancer diagnosed in advanced stages has a high recurrence rate. A low recurrence rate indicates successful curative surgical treatment. The highest recurrence rate was reported after Hartmann procedure (which was usually performed as an emergency operation for locally advanced lesions).

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

SIMONE, CARMINE. "PLATYPNEA-ORTHODEOXIA POST PNEUMONECTOMY FOR LUNG CANCER". Chest 160, n.º 4 (outubro de 2021): A60. http://dx.doi.org/10.1016/j.chest.2021.07.092.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Matuschek, Christiane, Danny Jazmati, Edwin Bölke, Bálint Tamaskovics, Stefanie Corradini, Wilfried Budach, David Krug et al. "Post-Neoadjuvant Treatment Strategies in Breast Cancer". Cancers 14, n.º 5 (28 de fevereiro de 2022): 1246. http://dx.doi.org/10.3390/cancers14051246.

Texto completo da fonte

Resumo:

Neoadjuvant chemotherapy enables close monitoring of tumor response in patients with breast cancer. Being able to assess tumor response during treatment provides an opportunity to evaluate new therapeutic strategies. Thus, for triple-negative breast tumors, it was demonstrated that additional immunotherapy could improve prognosis compared with chemotherapy alone. Furthermore, adjuvant therapy can be escalated or de-escalated correspondingly. The CREATE-X trial randomly assigned HER2-negative patients with residual tumor after neoadjuvant therapy to either observation or capecitabine. In HER2-negative patients with positive BRCA testing, the OlympiA study randomly assigned patients to either observation or olaparib. HER2-positive patients without pathologic remission were randomly assigned to trastuzumab or trastuzumab–emtansine within the KATHERINE study. These studies were all able to show an improvement in oncologic outcome associated with the escalation of therapy in patients presenting with residual tumor after neoadjuvant treatment. On the other hand, this individualization of therapy may also offer the possibility to de-escalate treatment, and thereby reduce morbidity. Among WSG-ADAPT HER2+/HR-, HER2-positive patients achieved comparable results without chemotherapy after complete remission following neoadjuvant treatment. In summary, the concept of post-neoadjuvant therapy constitutes a great opportunity for individualized cancer treatment, potentially improving outcome. In this review, the most important trials of post-neoadjuvant therapy are compiled and discussed.

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

&NA;. "Post-tamoxifen letrozole beneficial for breast cancer". Inpharma Weekly &NA;, n.º 1512 (novembro de 2005): 11. http://dx.doi.org/10.2165/00128413-200515120-00029.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

SHIELD, P. W., B. DAUNTER e R. G. WRIGHT. "Post-irradiation cytology of cervical cancer patients". Cytopathology 3, n.º 3 (junho de 1992): 167–82. http://dx.doi.org/10.1111/j.1365-2303.1992.tb00043.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Brydoy, M., S. Fossa, O. Klepp, E. Wist, R. Bremnes e O. Dahl. "Post-treatment paternity in testicular cancer survivors". Journal of Clinical Oncology 22, n.º 14_suppl (15 de julho de 2004): 4527. http://dx.doi.org/10.1200/jco.2004.22.14_suppl.4527.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Bartelink, H. "Breast cancer: Post-mastectomy radiotherapy: recommended standards". Annals of Oncology 11 (2000): 7–12. http://dx.doi.org/10.1093/annonc/11.suppl_3.7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Cooper, Sian, Toby Pillinger, Imtiaz Ahmed, Konrad Wolfe e Sidath H. Liyanage. "Perineal recurrence of prostate cancer post-brachytherapy". BJR|case reports 5, n.º 3 (setembro de 2019): 20180104. http://dx.doi.org/10.1259/bjrcr.20180104.

Texto completo da fonte

Resumo:

We present a rare case of perineal recurrence of prostate cancer post low dose rate brachytherapy. Increased levels of prostate-specific antigen were recorded 12 years post brachytherapy. Pelvic CT and MRI visualized a nodular lesion in the perineum, and positron emission tomography demonstrated choline-avidity. Ultrasound-guided biopsy of the nodule was performed, yielding histology consistent with prostatic adenocarcinoma. Metastatic prostatic seeding to the perineum is a rare complication of brachytherapy. We discuss the putative mechanism, approach to diagnosis, and management.

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Barbetakis, Nikolaos, Christos Asteriou, Athanassios Kleontas e Christos Lafaras. "Post-pericardiotomy syndrome following lung cancer surgery". Interactive CardioVascular and Thoracic Surgery 11, n.º 6 (1 de dezembro de 2010): 871. http://dx.doi.org/10.1510/icvts.2010.248948a.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!